Antibiotic Resistance Market Analysis - Global Industry Size, Share, Trends and Forecast 2022 - 2030
The global antibiotic resistance market size is anticipated to reach US$ 12.11 Bn by 2026 with considerable CAGR over 5.5% over the forecast period 2018-2026, according to a new report by Acumen Research and Consulting.
- Last Updated: 18 Dec 2018
- Report Code: ARC933
- Category: Healthcare and Pharmaceuticals
Report coverage
| Market | Antibiotic Resistance Market |
|---|---|
| Analysis Period | 2018 - 2026 |
| Base Year | 2018 |
| Forecast Data | 2018 - 2026 |
| Segments Covered | By Intervention, By Distribution Method and By Geography |
| Regional Scope | North America, Europe, Asia Pacific, Latin America, and Middle East & Africa |
| Key Companies Profiled | TPfizer, Merck, Allergan, The Medicines Company, Melinta Therapeutics, Phage Technologies S.A, Tetraphase Pharmaceuticals, Nabriva Therapeutics. Macrolide Pharmaceuticals, Nemesis Bioscience, Westway Health, AmpliPhi Biosciences and BioVersys GmbH. |
| Report Coverage |
Market Trends, Drivers, Restraints, Competitive Analysis, Player Profiling, Regulation Analysis |
| Customization Scope | 10 hrs of free customization and expert consultation |
Market Segmentation
Market By Disease
- Complicated Urinary Tract Infection (cUTI)
- Complicated Intra-Abdominal Infections (cIAI)
- Blood Stream Infections (BSI)
- Clostridium difficile infections (CDI)
- Acute Bacterial Skin and Skin Structure Infections (ABSSSI)
- Hospital Acquired Bacterial Pneumonia/Ventilator (HABP/VABP)
- Community Acquired Bacterial Pneumonia (CABP)
Market By Pathogen
- Acinetobacter baumannii (Carbapenem-Resistant and ESBL-producing)
- Pseudomonas aeruginosa (Carbapenem-Resistant)
- Staphylococcus Aureus (Methicillin-Resistant)
- E. coli/K. pneumoniae (Carbapenem-Resistant)
- Streptococcus pneumoniae (Penicillin-Non-Susceptible)
- Clostridium difficile (Cephalosporin-Resistant, Tetracycline-Resistant)
- Enterococcus faecium (Vancomycin-Resistant)
- Haemophilus Influenzae (Ampicillin-Resistant)
Market By Drug Class
- Oxazolidinones
- Lipoglycopeptides
- Tetracyclines
- Cephalosporins
- Combination therapies
- Others
Market By Geography
- North America
- U.S.
- Canada
- Mexico
- Europe
- UK
- Germany
- France
- Rest of Europe
- Asia-Pacific
- China
- Japan
- India
- Australia
- Rest of Asia-Pacific
- Latin America
- Brazil
- Chile
- Rest of Latin America
- Middle East and Africa (MEA)
- South Africa
- Saudi Arabia
- Rest of MEA
Market Participants
Looking for discounts, bulk pricing, or custom solutions? Contact us today at sales@acumenresearchandconsulting.com
Frequently Asked Questions
Other Healthcare and Pharmaceuticals Reports
March 2021
December 2024
April 2021
September 2022